Online inquiry

IVTScrip™ mRNA-Anti-IL12B, ABT-874(Cap 0, Pseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ1355MR)

This product GTTS-WQ1355MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & Pseudo-UTP. It ecodes the monoclonal antibody that targets IL12B gene. The antibody can be applied in Crohn's disease (CD) research.
Specifications
Product type mRNA
Modified bases Pseudo-UTP
5' Cap Cap 0
Species Homo sapiens
RefSeq NM_002187.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 3593
UniProt ID P29460
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-IL12B, ABT-874(Cap 0, Pseudo-UTP, 120 nt-poly(A)) (GTTS-WQ1355MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ12423MR IVTScrip™ mRNA-Anti-IFNG, NI-0501(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA NI-0501
GTTS-WQ2732MR IVTScrip™ mRNA-Anti-IL23A, AMG-139(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA AMG-139
GTTS-WQ2833MR IVTScrip™ mRNA-Anti-NGF, AMG-403(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA AMG-403
GTTS-WQ9259MR IVTScrip™ mRNA-Anti-CEACAM5, IMMU-130(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA IMMU-130
GTTS-WQ7700MR IVTScrip™ mRNA-Anti-ERBB2, GEXMab73(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA GEXMab73
GTTS-WQ3319MR IVTScrip™ mRNA-Anti-lukG&lukH, ASN-100(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA ASN-100
GTTS-WQ12964MR IVTScrip™ mRNA-Anti-TNFRSF12A, PDL 192(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA PDL 192
GTTS-WQ1707MR IVTScrip™ mRNA-Anti-Dabigatran, aDabi-Fab(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA aDabi-Fab
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW